PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19139972-8 2009 Bosentan treatment significantly reduced plasma Ang II levels, while L-158,809 treatment significantly increased vascular ET-1-immunoreactivity in fructose-fed rats. Bosentan 0-8 angiotensinogen Rattus norvegicus 48-54 11230326-11 2001 Bosentan also blocked Ang II-induced hypertension (from 135+/-4 to 139+/-3 mm Hg) but did not decrease isoprostanes (146+/-14 pg/mL). Bosentan 0-8 angiotensinogen Rattus norvegicus 22-28 17024690-6 2007 Treatment of cells with ET antagonist bosentan and NHE-1 inhibitor cariporide prevented glucose-induced cardiomyocyte hypertrophy and expression of ANP, Agt, and iNOS. Bosentan 38-46 angiotensinogen Rattus norvegicus 153-156 14615287-9 2003 Bosentan, an endothelin (ET) receptor antagonist, reduced Ang II-increased ICaT density without affecting the amount of CaV3.1 mRNA. Bosentan 0-8 angiotensinogen Rattus norvegicus 58-64 14615287-10 2003 Finally, cotreatment with bosentan and UO126 abolished the Ang II-increased ICaT density. Bosentan 26-34 angiotensinogen Rattus norvegicus 59-65 11463769-4 2001 In the presence of bosentan, pressor and renal vasoconstrictor responses to low-dose angiotensin II were blunted (P<0.02 and P<0.01, respectively), and the results with BQ-123 were similar. Bosentan 19-27 angiotensinogen Rattus norvegicus 85-99 11463769-6 2001 In contrast, high-dose angiotensin II caused natriuretic and diuretic effects that were completely prevented by bosentan. Bosentan 112-120 angiotensinogen Rattus norvegicus 23-37 9449383-4 1998 Although bosentan alone did not affect SAP, the development of Ang II-induced hypertension was entirely prevented by the endothelin antagonist. Bosentan 9-17 angiotensinogen Rattus norvegicus 63-69 10886569-7 2000 Bosentan treatment in the obstructed group prevented these Ang II-induced effects and did not have any effect on the sham-operated kidney. Bosentan 0-8 angiotensinogen Rattus norvegicus 59-65 9449383-6 1998 The marked increase in albuminuria observed in rats infused with Ang II (2524+/-961 versus 91+/-6 microg/24 h in control rats) was prevented by bosentan. Bosentan 144-152 angiotensinogen Rattus norvegicus 65-71 9449383-7 1998 Similarly, bosentan abolished the increase in heart weight index (from 2.96+/-0.03 to 3.41+/-0.08 mg/g body weight) and carotid media thickness (from 73+/-14 to 108+/-6 microm) induced by Ang II infusion. Bosentan 11-19 angiotensinogen Rattus norvegicus 188-194 9404419-0 1997 [Bosentan attenuates the hypertensive effect of angiotensin II in rats]. Bosentan 1-9 angiotensinogen Rattus norvegicus 48-62 9403591-0 1997 Bosentan prevents preglomerular alterations during angiotensin II hypertension. Bosentan 0-8 angiotensinogen Rattus norvegicus 51-65 9403591-10 1997 AR were inhibited in Ang II-treated rats along ILA and AA; Ang II-induced AR changes were prevented by bosentan. Bosentan 103-111 angiotensinogen Rattus norvegicus 21-27 9403591-10 1997 AR were inhibited in Ang II-treated rats along ILA and AA; Ang II-induced AR changes were prevented by bosentan. Bosentan 103-111 angiotensinogen Rattus norvegicus 59-65 9401758-14 1997 The AII-induced femoral vasodilatation was suppressed by blockade of nitric oxide (NO) synthesis with NG-nitro-L-arginine methyl ester (L-NAME, 40 mumol kg-1) and reversed to vasoconstriction when L-NAME was combined with indomethacin (30 mumol kg-1), but was left unaltered by antagonism of endothelin ETA/B receptors with bosentan (37 mumol kg-1). Bosentan 324-332 angiotensinogen Rattus norvegicus 4-7 9404419-4 1997 [table: see text] Tail-cuff pressure increased from 126 +/- 4 to 164 +/- 8 mmHg in rats infused with AngII alone whereas it did not change (basal: 132 +/- 3 and final: 135 +/- 3 mmHg: p = NS) when bosentan was coadministered with AngII. Bosentan 197-205 angiotensinogen Rattus norvegicus 101-106 9404419-6 1997 In AngII-perfused rats, CO, RBF, TPR and RVR were restored by bosentan to values observed in untreated rats. Bosentan 62-70 angiotensinogen Rattus norvegicus 3-8 9404419-7 1997 These results indicate that blockade of endothelin A and B receptors by bosentan prevents the development of AngII-induced hypertension through attenuation of the effect of AngII on vascular tone and suggest that endothelin is an important mediator of the vasoconstrictor action of angiotensin II in rats. Bosentan 72-80 angiotensinogen Rattus norvegicus 109-114 9404419-7 1997 These results indicate that blockade of endothelin A and B receptors by bosentan prevents the development of AngII-induced hypertension through attenuation of the effect of AngII on vascular tone and suggest that endothelin is an important mediator of the vasoconstrictor action of angiotensin II in rats. Bosentan 72-80 angiotensinogen Rattus norvegicus 173-178 8901827-5 1996 Strikingly, bosentan pretreatment blunted the increases in blood pressure, the fall in cardiac output, and the decreases in conductance evoked by lower doses of Ang II but not higher doses of the peptide. Bosentan 12-20 angiotensinogen Rattus norvegicus 161-167 7485537-8 1995 Both ramipril (an angiotensin-converting enzyme inhibitor, 7.5 mg/kg daily) and bosentan (a nonselective ET receptor antagonist, 100 mg/kg daily) substantially reduced the elevation in ET-1 mRNA seen in the clipped kidney after 2 days, suggesting that the generation of angiotensin II and the action of ET itself are involved in the mechanism by which clipping stimulates ET-1 expression. Bosentan 80-88 angiotensinogen Rattus norvegicus 270-284